Aprogen

Aprogen updated the terms of convertible bonds to raise US$14.6M, about 35.6% of its market value.

This is a correction notice to a prior disclosure regarding the acquisition of stocks and investment securities of GPCR Co., Ltd. (GPCR Co., Ltd.), a subsidiary. The correction changes the scheduled acquisition date from November 21, 2026 to April 10, 2027, and adjusts the payment dates for two tranches of third-party allotted paid-in capital increases (428,572 shares and 571,427 shares), with the Company acquiring a total of 1,428,571 shares for US$7.25M and obtaining a 12.15% ownership stake.

Aprogen reports completion of payment on its 34th series bearer-form unsecured private placement convertible bonds, with a planned and actual issuance amount of US$36M, paid in on 2026-08-21.

Aprogen reports completion of payment on its 33rd series bearer-form unsecured private placement convertible bonds, with a planned and actual issuance amount of US$1.44M, paid in on 2026-08-21.

Aprogen disclosed convertible bonds to raise US$35.3M, about 89.0% of its market value.

Aprogen disclosed convertible bonds to raise US$1.41M, about 3.6% of its market value.

Apton Co., Ltd., a subsidiary of Aprogen, amended its June 25, 2026 report on an 11th-series convertible bond issuance, cutting the issuance amount from US$10.2M to US$6.78M and moving the subscription date from June 25 to July 24, 2026, with the conversion price reset to US$0.68 per share.

Aprogen completed payment on 2026-07-23 for its 32nd unregistered unsecured private-placement convertible bonds, raising US$1.36M, under a board resolution originally dated 2026-07-13.

Aprogen Biologics, a subsidiary of Aprogen, resolved on July 14, 2026 to issue 1,087,548 new common shares via third-party allotment to its parent, Aprogen, at US$1.24 per share (a 10.0% discount to the US$1.37 base price) to raise US$1.34M in operating funds, with payment due July 27, 2026 and listing expected August 14, 2026.

Aprogen disclosed convertible bonds to raise US$1.34M, about 3.6% of its market value.

Aprogen amended its June 25, 2026 material event report for subsidiary APTN Inc.'s US$2.3M third-party-placement rights offering (3,500,000 common shares at US$0.66 per share), changing the payment date from July 7 to July 15, 2026, the new-share listing date from August 11 to August 19, 2026, and the allottee from Shin Dong-seung to SDS Holdings Co., Ltd.

Aprogen disclosed convertible bonds to raise US$6.65M, about 17.8% of its market value.

Aprogen disclosed convertible bonds to raise US$8.15M, about 21.4% of its market value.

Aprogen updated the terms of convertible bonds to raise US$27.2M, about 71.2% of its market value.

Aprogen disclosed a private placement (third-party allotment) to raise US$1.33M, about 3.6% of its market value.

Aprogen updated a previously disclosed supply contract with POSCO, now worth US$5.75M, about 11.12% of its recent annual revenue, running through May 2026.

Aprogen reported a subsidiary's consolidated results for FY2025: revenue of US$51.1M (+8.7% year on year), an operating loss of US$42.2M and a net loss of US$114M.

Aprogen reported a subsidiary's consolidated results for FY2025: revenue of US$6.85M (−40.2% year on year), an operating loss of US$1.6M (from a profit a year earlier) and a net loss of US$2.47M.

Aprogen updated a previously disclosed supply contract with POSCO, now worth US$6.01M, about 11.04% of its recent annual revenue, running through Mar 2026.

Aprogen reported consolidated results for FY2025: revenue of US$81.7M (−21.41% year on year), an operating loss of US$66.2M and a net loss of US$95.4M.